A Look Into Healthcare Sector Value Stocks
Portfolio Pulse from Benzinga Insights
The article discusses notable value stocks in the healthcare sector, highlighting their low price-to-earnings (P/E) multiples, which suggest they may be undervalued. The stocks mentioned are Cross Country Healthcare (CCRN), Nuwellis (NUWE), First Wave BioPharma (FWBI), Voyager Therapeutics (VYGR), and Panbela Therapeutics (PBLA). The article also provides recent earnings per share data for these companies, indicating their financial performance.
December 11, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cross Country Healthcare has a low P/E of 7.23, with a recent decrease in earnings per share from $0.69 to $0.39, indicating potential undervaluation.
While CCRN's low P/E suggests undervaluation, the decrease in earnings per share could be a concern for short-term investors, leading to a neutral score.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Voyager Therapeutics has a P/E of 6.69 with a slight decrease in EPS from -$0.51 to -$0.59, which may concern investors.
VYGR's low P/E ratio is attractive, but the decrease in EPS could be a red flag, leading to a neutral impact on the short-term stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
First Wave BioPharma's P/E is at 0.01, with an EPS increase from -$1.89 to -$0.46, possibly indicating a value opportunity.
FWBI's extremely low P/E and improved earnings per share suggest it may be undervalued, which could be positive for short-term price movement.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Nuwellis has an extremely low P/E of 0.02 and showed improvement in earnings per share from -$3.65 to -$1.81, which may attract value investors.
NUWE's very low P/E and better earnings per share could signal a turnaround, making it potentially attractive to value investors, hence a positive score.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Panbela Therapeutics, with a P/E of 0.0 and a significant EPS increase from -$7.95 to -$2.42, may catch the eye of value investors.
PBLA's significant improvement in earnings per share and a P/E of 0.0 could indicate a strong value proposition, potentially leading to a positive price impact.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80